There are 702 resources available
284P - Efficacy and safety of stereotactic body radiation therapy combined with surufatinib and sintilimab for patients with biliary tract cancer failed with standard therapy
Presenter: Ai Huang
Session: Poster Display session
285P - Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial
Presenter: Lorenza Rimassa
Session: Poster Display session
286P - TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort
Presenter: Jiajia Yuan
Session: Poster Display session
287P - Association of progression-free survival (PFS) with overall survival (OS) in advanced biliary tract cancer (BTC): A trial- and patient-level analysis
Presenter: Florian Castet
Session: Poster Display session
288P - Recent advances in systemic therapy for advanced biliary tract cancer: A systematic review and meta-analysis
Presenter: Zhihao Li
Session: Poster Display session
289P - Treatment outcomes in previously treated patients with advanced/metastatic HER2+ biliary tract cancer: A systematic review
Presenter: Suzy Paisley
Session: Poster Display session
290P - Global epidemiology trends in biliary tract cancer: A targeted literature review
Presenter: John Bridgewater
Session: Poster Display session
291P - Tumor biology, treatment patterns, and survival outcomes in young-onset biliary tract cancers
Presenter: Anthony Turpin
Session: Poster Display session
292P - Extended molecular profiling (EMP) and access to targeted treatment (TT) in advanced biliary tract cancer (BTC): Results from the Italian cholangiocarcinoma dataset (ANITA)
Presenter: Virginia Genovesi
Session: Poster Display session
293P - Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
Presenter: Andrea Casadei Gardini
Session: Poster Display session